Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Sarepta Therapeutics
Pharma
Pfizer's DMD loss is Sarepta's gain: analysts
With a phase 3 miss and severe safety signals, Pfizer's Duchenne muscular dystrophy gene therapy candidate isn't stacking up to Sarepta's Elevidys.
Zoey Becker
Jun 13, 2024 10:58am
Italfarmaco wins FDA's blessing for nonsteroidal DMD therapy
Mar 22, 2024 11:05am
Elevidys gains steam amid Sarepta's efforts to widen FDA label
Feb 29, 2024 4:11pm
Sarepta's Elevidys expansion bid gets fast review without adcomm
Feb 16, 2024 11:05am
Catalent pins hopes on GLP-1s, Sarepta's Elevidys
Nov 15, 2023 11:50am
FDA's Marks went against reviewers' call on Sarepta's Elevidys
Jun 26, 2023 11:35am
